share_log

Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $850 Price Target

Benzinga ·  Jan 9 09:19

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $850 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment